Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
TARA
Protara Therapeutics, Inc.
TARA-2.00 is a cell therapy platform, representing the company’s lead product modality.
|
$239.21M |
$5.82
-6.13%
|
|
TOI
The Oncology Institute, Inc.
Radiopharmaceutical therapy is a modality offered in their oncology practice.
|
$238.44M |
$2.56
+0.39%
|
|
BNR
Burning Rock Biotech Limited
Biopharma services segment indicates outsourced R&D, clinical testing, and development support.
|
$236.69M |
$21.21
-3.48%
|
|
OBIO
Orchestra BioMed Holdings, Inc.
Virtue SAB represents a drug-delivery platform delivering extended-release sirolimus to the vessel wall.
|
$236.32M |
$4.38
+1.04%
|
|
ALEC
Alector, Inc.
Latozinemab and AL101 are monoclonal antibody therapeutics in the pipeline.
|
$234.68M |
$2.00
-6.98%
|
|
ACHV
Achieve Life Sciences, Inc.
Cytisinicline is an oral small-molecule therapeutic candidate for smoking cessation, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$234.06M |
$4.42
-3.60%
|
|
CNTX
Context Therapeutics Inc.
The company's pipeline centers on T cell engaging bispecific antibodies (CTIM-76, CT-95, CT-202).
|
$233.23M |
$2.85
+9.81%
|
|
NVCT
Nuvectis Pharma, Inc.
Nuvectis' lead asset NXP900 is a cancer-targeting therapy (SRC/YES1 kinase inhibitor), placing the company in Biotech - Oncology.
|
$231.30M |
$9.05
+0.22%
|
|
VYGR
Voyager Therapeutics, Inc.
Voyager’s core offerings are gene therapies and gene-delivery platforms, including APOE and tau-targeted approaches.
|
$229.09M |
$3.94
-4.72%
|
|
SLRN
Acelyrin, Inc.
Lonigutamab is a monoclonal antibody therapeutic (IGF-1R) being developed as a treatment for TED, aligning with Monoclonal Antibody Therapeutics.
|
$228.61M |
$2.27
|
|
ASMB
Assembly Biosciences, Inc.
Assembly Biosciences develops small-molecule antiviral therapeutics, including HSV helicase-primase inhibitors, HDV entry inhibitors, HBV capsid assembly modulators, and NNPI programs.
|
$228.56M |
$27.58
-7.42%
|
|
QNCX
Quince Therapeutics, Inc.
Quince's AIDE platform is a drug-delivery platform encapsulating drugs in autologous red blood cells.
|
$226.67M |
$4.28
-2.73%
|
|
STTK
Shattuck Labs, Inc.
SL-325 is a monoclonal antibody targeting DR3, making Monoclonal Antibody Therapeutics a direct product category.
|
$226.58M |
$5.11
+8.03%
|
|
CPMV
Mosaic ImmunoEngineering Inc.
Lead oncology candidate MIE-101 defines CPMV's core product focus in cancer therapy.
|
$222.38M |
$0.70
|
|
OABI
OmniAb, Inc.
OmniAb's core offering is the Antibody Discovery Platform enabling rapid generation of human antibodies through engineered transgenic animals and associated discovery tools.
|
$222.09M |
$2.00
+10.22%
|
|
PEPG
PepGen Inc.
PepGen's PGN-EDODM1 is an oligonucleotide therapeutic targeting DM1, aligning directly with Oligonucleotide Therapeutics.
|
$221.73M |
$6.75
+5.14%
|
|
FENC
Fennec Pharmaceuticals Inc.
Direct product in oncology/supportive care with FDA-approved PEDMARK therapy for cisplatin-induced ototoxicity.
|
$210.13M |
$7.74
+2.45%
|
|
HRTX
Heron Therapeutics, Inc.
Biochronomer drug-delivery technology is a platform enabling extended-release formulations across Heron's products.
|
$207.20M |
$1.01
-10.18%
|
|
ANIK
Anika Therapeutics, Inc.
Non-opioid pain management solutions through HA injections address OA pain.
|
$207.09M |
$14.26
-0.70%
|
|
IRD
Opus Genetics, Inc.
Core product area: AAV-based gene therapies for inherited retinal diseases (OPGx-LCA5, OPGx-BEST1).
|
$206.68M |
$3.65
+5.80%
|
|
CRGX
CARGO Therapeutics, Inc. Common Stock
CRGX's core offerings are oncology CAR-T therapies (firi-cel, CRG-23), placing it in Biotech - Oncology.
|
$206.13M |
$4.47
|
|
RNAC
Cartesian Therapeutics, Inc.
Lead platform is an autologous cell therapy using mRNA CAR-T, a direct cell-therapy product line.
|
$204.64M |
$6.89
-12.45%
|
|
CHRS
Coherus Oncology, Inc.
LOQTORZI is a differentiated PD-1 monoclonal antibody and commercial oncology product, aligning with Monoclonal Antibody Therapeutics.
|
$204.56M |
$1.76
|
|
CGEN
Compugen Ltd.
Company focus and programs are centered in oncology/immuno-oncology, qualifying under Biotech - Oncology.
|
$200.17M |
$2.06
-3.97%
|
|
GALT
Galectin Therapeutics Inc.
Lead cancer therapy program belapectin demonstrates oncology-focused Biotech activity and immuno-oncology potential.
|
$199.23M |
$3.04
-2.41%
|
|
DERM
Journey Medical Corporation
Emrosi is an oral small molecule therapeutic (minocycline extended-release) and represents Journey Medical's flagship product launched in 2025.
|
$196.00M |
$7.85
-2.36%
|
|
NKTX
Nkarta, Inc.
Nkarta is developing allogeneic CAR NK cell therapy (NKX019) for autoimmune diseases, directly fitting the Cell Therapy product category.
|
$193.90M |
$2.46
-9.89%
|
|
MDWD
MediWound Ltd.
MediWound's core products are enzymatic proteins/enzymes (NexoBrid, EscharEx) used for wound debridement, aligning with Recombinant Proteins & Enzymes.
|
$191.41M |
$17.41
-1.08%
|
|
IMRX
Immuneering Corporation
Atebimetinib (IMM-1-104) is an oral small-molecule therapeutic in clinical trials.
|
$187.77M |
$4.98
-3.68%
|
|
TLSA
Tiziana Life Sciences Ltd
TLSA's lead product Foralumab is a fully human monoclonal antibody therapeutic, placing the company in Monoclonal Antibody Therapeutics.
|
$185.78M |
$1.43
|
|
SGMT
Sagimet Biosciences Inc.
Sagimet's lead and second FASN inhibitors (denifanstat, TVB-3567) are oral small-molecule therapeutics, directly aligning with this tag.
|
$185.70M |
$5.71
-2.81%
|
|
MOLN
Molecular Partners AG
Core focus on oncology therapeutics built on the DARPin platform.
|
$184.52M |
N/A
|
|
NTHI
Neonc Technologies Holdings, Inc.
Directly produces oncology-focused biotech therapies; lead programs NEO100/NEO212 targeting brain cancers.
|
$184.50M |
$9.39
-2.44%
|
Showing page 14 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
